SynthesisPloS one2012
Gene-expression signature predicts postoperative recurrence in stage I non-small cell lung cancer patients.
Synthesis in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Artificial intelligence-based non-small cell lung cancer transcriptome RNA-sequence analysis technology selection guide.Frontiers in bioengineering and biotechnology · 2023Pooled it
- Integrated systems biology reveals an 8-gene signature predicting early-stage lung adenocarcinoma progression and patient survival.Scientific reports · 2025Article
- LINC00894, YEATS2-AS1, and SUGP2 genes as novel biomarkers for N0 status of lung adenocarcinoma.Scientific reports · 2025Article
- Inflammation in the tumor-adjacent lung as a predictor of clinical outcome in lung adenocarcinoma.Nature communications · 2023Article
- Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors.Frontiers in immunology · 2023Review
- Identification of an inflammatory response signature associated with prognostic stratification and drug sensitivity in lung adenocarcinoma.Scientific reports · 2022Article
- A 5-Pathway Signature Predicts Prognosis Based on Immune-Derived lncRNAs in Patients with Breast Cancer.Journal of oncology · 2022Article
- Use tumor suppressor genes as biomarkers for diagnosis of non-small cell lung cancer.Scientific reports · 2021Article
- An integrated approach to biomarker discovery reveals gene signatures highly predictive of cancer progression.Scientific reports · 2020Article
- Elevated CELSR3 expression is associated with hepatocarcinogenesis and poor prognosis.Oncology letters · 2020Article
- A novel signature based on microvascular invasion predicts the recurrence of HCC.Journal of translational medicine · 2020Article
- High dimensional model representation of log-likelihood ratio: binary classification with expression data.BMC bioinformatics · 2020Article
- Deep gene selection method to select genes from microarray datasets for cancer classification.BMC bioinformatics · 2019Article
- A robust six-gene prognostic signature for prediction of both disease-free and overall survival in non-small cell lung cancer.Journal of translational medicine · 2019Article
- Network Pharmacology-Based identification of pharmacological mechanism of SQFZ injection in combination with Docetaxel on lung cancer.Scientific reports · 2019Article
- Emerging Prognostic Biomarkers in Testicular Germ Cell Tumors: Looking Beyond Established Practice.Frontiers in oncology · 2018Article
- Time-dependent ROC curve analysis in medical research: current methods and applications.BMC medical research methodology · 2017Article
- A novel seven-long non-coding RNA signature predicts survival in early stage lung adenocarcinoma.Oncotarget · 2017Article
- Identification of differentially expressed miRNAs in individual breast cancer patient and application in personalized medicine.Oncogenesis · 2016Article
- Improving the pathologic evaluation of lung cancer resection specimens.Translational lung cancer research · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
About 30% stage I non-small cell lung cancer (NSCLC) patients undergoing resection will recur. Robust prognostic markers are required to better manage therapy options. The purpose of this study is to develop and validate a novel gene-expression signature that can predict tumor recurrence of stage I NSCLC patients. Cox proportional hazards regression analysis was performed to identify recurrence-related genes and a partial Cox regression model was used to generate a gene signature of recurrence in the training dataset -142 stage I lung adenocarcinomas without adjunctive therapy from the Director's Challenge Consortium. Four independent validation datasets, including GSE5843, GSE8894, and two other datasets provided by Mayo Clinic and Washington University, were used to assess the prediction accuracy by calculating the correlation between risk score estimated from gene expression and real recurrence-free survival time and AUC of time-dependent ROC analysis. Pathway-based survival analyses were also performed. 104 probesets correlated with recurrence in the training dataset. They are enriched in cell adhesion, apoptosis and regulation of cell proliferation. A 51-gene expression signature was identified to distinguish patients likely to develop tumor recurrence (Dxy = -0.83, P<1e-16) and this signature was validated in four independent datasets with AUC >85%. Multiple pathways including leukocyte transendothelial migration and cell adhesion were highly correlated with recurrence-free survival. The gene signature is highly predictive of recurrence in stage I NSCLC patients, which has important prognostic and therapeutic implications for the future management of these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.